|
41 Companies |
|
50 Products |
|
50 Products |
|
53 Mechanisms of Action |
|
1 Trial |
|
299 News |
|
| «123456 |
- cyclosporin A microemulsion / Generic mfg.
New P2 trial: CYPRESS: Low Dose Cyclosporin A in Primary Sj (clinicaltrials.gov) - Sep 24, 2012
P2, N=30, Recruiting, Sponsor: Charite University, Berlin, Germany
- | clonidine/oxybutynin (OP-014) / Orient Europharma
Trial completion: A Relative Efficacy and Safety Study of OC Oral Solution for Sialorrhoea in Patients With Parkinson's Disease (clinicaltrials.gov) - Sep 20, 2012
P2, N=24, Completed, Sponsor: Orient Pharma Co., Ltd.
Recruiting --> Completed
- selenomethionine (SLM) / University of Iowa, Holden Comprehensive Cancer Center
New P2 trial, Metastases: Selenomethionine in Reducing Mucositis in Patients With Locally Advanced Head and Neck Cancer Who Are Receiving Cisplatin and Radiation Therapy (clinicaltrials.gov) - Sep 6, 2012
P2, N=18, Completed, Sponsor: Roswell Park Cancer Institute
- Benlysta (belimumab) / GSK
Trial completion: Efficacy and Safety of Belimumab in Primary Sj (clinicaltrials.gov) - Sep 2, 2012
P2, N=15, Completed, Sponsor: University of Udine
Recruiting --> Completed Recruiting --> Completed
- | dovitinib (TKI258) / Novartis, Oncoheroes
New P2 trial, Metastases: DOVE: A Phase II Study of Dovitinib in Recurrent and/or Metastatic Adenoid Cystic Carcinoma of the Salivary Glands (clinicaltrials.gov) - Aug 30, 2012
P2, N=20, Active, not recruiting, Sponsor: Ontario Clinical Oncology Group (OCOG)
- baminercept (BG 9924) / Biogen
Enrollment open: Baminercept, a Lymphotoxin-Beta Receptor Fusion Protein, for Treatment of Sj (clinicaltrials.gov) - Aug 15, 2012
P2, N=72, Recruiting, Sponsor: National Institute of Allergy and Infectious Diseases (NIAID)
Recruiting --> Completed Not yet recruiting --> Recruiting
- dasatinib / Generic mfg.
Enrollment closed, Metastases: Dasatinib in Treating Patients With Recurrent or Metastatic Malignant Salivary Gland Tumors (clinicaltrials.gov) - Aug 14, 2012
P2, N=65, Active, not recruiting, Sponsor: National Cancer Institute (NCI)
Not yet recruiting --> Recruiting Recruiting --> Active, not recruiting
- MK-2206 / Merck (MSD)
Trial initiation date, Metastases: Akt Inhibitor MK2206 in Treating Patients With Progressive, Recurrent, or Metastatic Adenoid Cyst Carcinoma (clinicaltrials.gov) - Aug 2, 2012
P2, N=15, Active, not recruiting, Sponsor: National Cancer Institute (NCI)
Recruiting --> Active, not recruiting Initiation date: Oct 2011 --> Aug 2012
- Xeomin (incobotulinumtoxinA) / Merz Pharma
New P2 trial: Incobotulinum Toxin A (Xeomin (clinicaltrials.gov) - Jul 26, 2012
P2, N=20, Recruiting, Sponsor: Beth Israel Deaconess Medical Center
- || New P2/3 trial: Drug-induced Xerostomia. Evaluation of Malic Acid 1%, Salivary Mucins and Buffering Capacity (clinicaltrials.gov) - Jul 25, 2012
P2/3, N=185, Recruiting, Sponsor: Universidad de Granada
- | New P1/2 trial: Green Tea Lozenges for the Management of Dry Mouth (clinicaltrials.gov) - Jul 22, 2012
P1/2, N=60, Recruiting, Sponsor: Georgia Regents University
- Erbitux (cetuximab) / Eli Lilly
New P1 trial, Metastases: Cetuximab and Everolimus in Treating Patients With Metastatic or Recurrent Colon Cancer or Head and Neck Cancer (clinicaltrials.gov) - Jul 9, 2012
P1, N=12, Completed, Sponsor: Fox Chase Cancer Center
- | Benlysta (belimumab) / GSK
Enrollment change, IO biomarker: BELISS: Efficacy and Safety of Belimumab in Subjects With Primary Sj (clinicaltrials.gov) - Jun 30, 2012
P2, N=20, Completed, Sponsor: Assistance Publique - H
Initiation date: Oct 2011 --> Aug 2012 N=15 --> 20
- | Benlysta (belimumab) / GSK
Trial completion, IO biomarker: BELISS: Efficacy and Safety of Belimumab in Subjects With Primary Sj (clinicaltrials.gov) - Jun 30, 2012
P2, N=20, Completed, Sponsor: Assistance Publique - H
N=15 --> 20 Recruiting --> Completed
- ||||||| hydroxychloroquine / Generic mfg.
Trial completion: JOQUER: Hydroxychloroquine Versus Placebo in Primary Sj (clinicaltrials.gov) - Jun 30, 2012
P3, N=120, Completed, Sponsor: Assistance Publique - H
Recruiting --> Completed Recruiting --> Completed
- Clinical: Effect of 0.1% Pilocarpine Mouthwash on Xerostomia (clinicaltrials.gov) - Jun 24, 2012
P=N/A, N=60, Completed, Sponsor: Jeong-seong Kwon
- Halaven (eribulin mesylate) / Eisai
New P2 trial, Metastases: Eribulin Mesylate in Treating Patients With Recurrent or Metastatic Salivary Gland Cancer (clinicaltrials.gov) - Jun 5, 2012
P2, N=29, Recruiting, Sponsor: University of Washington
- Trial completion, Surgery: Salivary Gland Surgery Before Radiation Therapy in Preventing Radiation-Caused Xerostomia in Patients With Head and Neck Cancer (clinicaltrials.gov) - May 31, 2012
P2, N=49, Completed, Sponsor: Radiation Therapy Oncology Group
Recruiting --> Completed Active, not recruiting --> Completed
- MK-2206 / Merck (MSD)
New P2 trial, Metastases: Akt Inhibitor MK2206 in Treating Patients With Progressive, Recurrent, or Metastatic Adenoid Cyst Carcinoma (clinicaltrials.gov) - May 22, 2012
P2, N=15, Active, not recruiting, Sponsor: National Cancer Institute (NCI)
- hydroxychloroquine / Generic mfg.
New P3 trial: Hydroxychloroquine Treatment of Dry Eyes in Patients With Primary Sj (clinicaltrials.gov) - May 15, 2012
P3, N=39, Completed, Sponsor: Seoul National University Hospital
- Enrollment change: The Effect of Honey on Xerostomia and Oral Mucositis (clinicaltrials.gov) - Apr 25, 2012
P2, N=60, Recruiting, Sponsor: Cyprus University of Technology
Active, not recruiting --> Completed N=40 --> 60
- | Rituxan (rituximab) / Biogen, Zenyaku Holdings, Roche
New P1/2 trial: Rituximab in IgG4-RD: A Phase 1-2 Trial (clinicaltrials.gov) - Apr 23, 2012
P1/2, N=30, Active, not recruiting, Sponsor: Massachusetts General Hospital
- ||||||| Trial completion: OGT Spray in the Management of Xerostomia in the Elderly (clinicaltrials.gov) - Apr 19, 2012
P3, N=74, Completed, Sponsor: Laboratoires CARILENE
N=40 --> 60 Terminated --> Completed
- | Enrollment change: Acupuncture in Treating Dry Mouth Caused By Radiation Therapy in Patients With Head and Neck Cancer (clinicaltrials.gov) - Apr 2, 2012
P3, N=240, Recruiting, Sponsor: M.D. Anderson Cancer Center
Terminated --> Completed N=150 --> 240
- Xeomin (incobotulinumtoxinA) / Merz Pharma
New P2 trial: Incobotulinum Toxin A for Sialorrhea in Parkinson's Disease (PD)/Parkinsonism and Amyotrophic Lateral Sclerosis (ALS) (clinicaltrials.gov) - Mar 25, 2012
P2, N=20, Recruiting, Sponsor: Beth Israel Deaconess Medical Center
- Myobloc (rimabotulinumtoxin B) / Supernus Pharma, Eisai
Trial completion: Study of Myobloc in the Treatment of Sialorrhea (Drooling) in Patients With Amyotrophic Lateral Sclerosis (ALS) (clinicaltrials.gov) - Mar 12, 2012
P2/3, N=20, Completed, Sponsor: The University of Texas Health Science Center at San Antonio
N=150 --> 240 Active, not recruiting --> Completed
- | baminercept (BG 9924) / Biogen
New P2 trial: Baminercept, a Lymphotoxin-Beta Receptor Fusion Protein, for Treatment of Sj (clinicaltrials.gov) - Mar 11, 2012
P2, N=72, Recruiting, Sponsor: National Institute of Allergy and Infectious Diseases (NIAID)
- | Botox (onabotulinumtoxin A) / GSK, AbbVie, Healis Therap
New P2 trial: ALS-TOX: Toxin Treatment for Amyotrophic Lateral Sclerosis (ALS) Related Sialorrhea (clinicaltrials.gov) - Mar 11, 2012
P2, N=90, Recruiting, Sponsor: Hospices Civils de Lyon
- New P2 trial, HEOR: TOQUAL: Impact of Tomotherapy on Xerostomia and Quality of Life of Patients With Cancer of the Upper Aero-digestive Tract (clinicaltrials.gov) - Mar 6, 2012
P2, N=44, Recruiting, Sponsor: Centre Francois Baclesse
- |||||||||| ProQuad (measles, mumps, rubella and varicella virus vaccine live) / Merck (MSD)
New P3 trial: Safety, Tolerability, and Immunogenicity of Measles, Mumps, Rubella, and Varicella (MMRV) Vaccine Made With an Alternative Manufacturing Process (AMP)(V221-027) (clinicaltrials.gov) - Feb 20, 2012
P3, N=1413, Completed, Sponsor: Merck Sharp & Dohme Corp.
- Enrollment closed: Making Decisions About the Measles-Mumps-Rubella Vaccine (clinicaltrials.gov) - Feb 9, 2012
P=N/A, N=79, Active, not recruiting, Sponsor: University of Michigan
Active, not recruiting --> Completed Recruiting --> Active, not recruiting
- Erbitux (cetuximab) / Eli Lilly, EMD Serono
Enrollment closed, IO biomarker, Metastases: Phase II Randomized Trial of the Combination of Cetuximab and Sorafenib or Single Agent Cetuximab (clinicaltrials.gov) - Feb 6, 2012
P2, N=88, Active, not recruiting, Sponsor: National Cancer Institute (NCI)
Recruiting --> Active, not recruiting Suspended --> Active, not recruiting
- Apolactoferrin (talactoferrin alfa) / Agennix, talactoferrin oral (oral rhLF) / Agennix
New P1 trial, Immunomodulating: Talactoferrin in Treating Patients With Relapsed or Refractory Non-Small Cell Lung Cancer or Squamous Cell Head and Neck Cancer (clinicaltrials.gov) - Feb 5, 2012
P1, N=4, Terminated, Sponsor: Stanford University
- | Trial initiation date: Proof-of-concept (PoC) Study of APD515 (clinicaltrials.gov) - Jan 11, 2012
P2, N=32, Completed, Sponsor: Acacia Pharma Ltd
Suspended --> Active, not recruiting Initiation date: Jun 2011 --> Sep 2011
- amifostine / Generic mfg.
Trial termination: Chemo/XRT +/- Amifostine to Assess Outcomes Related to Xerostomia, Mucositis, & Dysphagia (clinicaltrials.gov) - Dec 6, 2011
P2, N=42, Terminated, Sponsor: Vanderbilt-Ingram Cancer Center
Initiation date: Jun 2011 --> Sep 2011 Active, not recruiting --> Terminated; funding became unavailable
- | cisplatin / Generic mfg.
New P2 trial: A Randomized Phase II Study of Adjuvant Concurrent Radiation and Chemotherapy Versus Radiation Alone in Resected High-Risk Malignant Salivary Gland Tumors (clinicaltrials.gov) - Dec 6, 2011
P2, N=120, Recruiting, Sponsor: King Faisal Specialist Hospital & Research Center
- | Trial completion: Effects of Mucoprotective Product on Xerostomia (clinicaltrials.gov) - Nov 7, 2011
P4, N=20, Completed, Sponsor: Camurus AB
Active, not recruiting --> Terminated; funding became unavailable Recruiting --> Completed
- | New P2 trial: The Effect of Honey on Xerostomia and Oral Mucositis (clinicaltrials.gov) - Nov 2, 2011
P2, N=60, Recruiting, Sponsor: Cyprus University of Technology
- Enrollment change: Xerostomia in Head and Neck Cancer Patients Receiving Radiation as the Primary Treatment Versus Patients Who Will Not Have Such a Procedure (clinicaltrials.gov) - Oct 5, 2011
P2, N=42, Completed, Sponsor: AHS Cancer Control Alberta
Recruiting --> Completed N=35 --> 42
- Trial completion: Xerostomia in Head and Neck Cancer Patients Receiving Radiation as the Primary Treatment Versus Patients Who Will Not Have Such a Procedure (clinicaltrials.gov) - Oct 5, 2011
P2, N=42, Completed, Sponsor: AHS Cancer Control Alberta
N=35 --> 42 Active, not recruiting --> Completed
- dexamethasone / Generic mfg.
Enrollment open: Dexamethasone Irrigation of the Parotid Glands in Primary Sj (clinicaltrials.gov) - Sep 11, 2011
P2, N=20, Recruiting, Sponsor: National Institute of Dental and Craniofacial Research (NIDCR)
Active, not recruiting --> Completed Not yet recruiting --> Recruiting
- Enrollment change: Evaluation of the Role of the Autonomic Nervous System in Sj(SqrRoot)(Delta)Gren s Syndrome (clinicaltrials.gov) - Aug 30, 2011
P=N/A, N=28, Completed, Sponsor: National Institute of Dental and Craniofacial Research (NIDCR)
Not yet recruiting --> Recruiting N=60 --> 28
- Trial completion: Evaluation of the Role of the Autonomic Nervous System in Sj(SqrRoot)(Delta)Gren s Syndrome (clinicaltrials.gov) - Aug 30, 2011
P=N/A, N=28, Completed, Sponsor: National Institute of Dental and Craniofacial Research (NIDCR)
N=60 --> 28 Recruiting --> Completed
- Trial termination: Electroacupuncture in Treating Chronic Dry Mouth Caused By Radiation Therapy in Patients With Head and Neck Cancer (clinicaltrials.gov) - Aug 10, 2011
P=N/A, N=30, Terminated, Sponsor: Mayo Clinic
Recruiting --> Completed Recruiting --> Terminated; Slow accrual; did not meet accrual goal
- || New P3 trial: The Use of Human Acellular Dermal Matrix to Improve Infraauricular Depressed Deformities and Frey's Syndrome (clinicaltrials.gov) - Aug 9, 2011
P3, N=70, Completed, Sponsor: West China Hospital